New York, New York-- (Newsfile Corp. - January 29, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into TransMedics Group, Inc. (NASDAQ: TMDX) for potential ...

NEW YORK CITY, NY / ACCESS Newswire / January 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

TransMedics Group Inc (TMDX) stock saw a modest uptick, ending the day at $67.03 which represents a slight increase of $5.96 or 9.76% from the prior close of $61.07. The stock opened at $61.47 and ...

TransMedics is facing allegations of fraud, organ trafficking, and unethical practices that have triggered shareholder ...

TransMedics' stock remains under pressure after a weak third quarter, reduced Q4 guidance, the exit of the company's CFO, and ...

Shares of organ transplant innovator TransMedics Group (NASDAQ: TMDX) fell 15.7% through Thursday trading, according to data ...

Headwaters Capital Management, an investment management company, released its fourth-quarter 2024 investor letter. A copy of ...

Check the time stamp on this data. Updated AI-Generated Signals for Transmedics Group Inc. (TMDX) available here: TMDX. Type ...

On Wednesday, Needham reiterated its Hold rating on TransMedics Group (NASDAQ:TMDX), following management's growth strategy update. The stock, which has seen a significant decline ...

View TransMedics Group, Inc. (TMDX) current and estimated P/E ratio data provided by Seeking Alpha.

TransMedics has had a tough stretch of late. Last Friday, short-seller Scorpion Capital published a short report on the company. Management vehemently denied wrongdoing, and said it was exploring ...

Shares of organ transplant innovator TransMedics Group (NASDAQ: TMDX) fell 15.7% through Thursday trading, according to data from S&P Global Market Intelligence. TransMedics was the target of an ...